Cancer Family
Esophageal Neoplasm
CI-CAN-00000174Explore in graph →
Non-malignant555 active trials6 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000174Explore in graph →
Clinical trials
2,208 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06960889 | A Retrospective Clinical Study Exploring Prognostic Factors in Esophageal Cancer Patients | active not recruiting | — | 500 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03102229 | Real-time Activity Monitoring to Prevent Admissions During RadioTherapy(RAMPART) | completed | N/A | 40 | Montefiore Medical CenterOTHER | 1 | Apr 13, 2026 |
| clinicaltrials |
| NCT05450484 | Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer(OPTIC) | completed | Phase 1 | 21 | University Medical Center GroningenOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05745857 | Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas(SLURP) | recruiting | Phase 2 | 25 | University Medical Center GroningenOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07518680 | A Clinical Study on the Effect of Massaging Tian Tu Acupoint on Coughing After Esophageal Surgery | not yet recruiting | N/A | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT00213486 | Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial | completed | Phase 2 | 43 | University Hospital, RouenOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05899985 | Magnetic Sentinel Lymph Node Mapping in Upper Gastro-Intestinal Cancer: A Feasibility Clinical Investigation(MAGMAP) | active not recruiting | N/A | 60 | Ferronova Pty LtdINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06504615 | Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France(METAGIO) | active not recruiting | — | 208 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03482791 | Proton Beam Therapy in the Treatment of Esophageal Cancer | active not recruiting | N/A | 22 | Washington University School of MedicineOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06654297 | Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas | active not recruiting | Phase 1 | 6 | West China HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07505186 | Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 45 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02366819 | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer | suspended | Phase 4 | 36 | University of ChicagoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT02530983 | Mayo Clinic Upper Digestive Disease Survey(UDD) | recruiting | — | 1,000 | Mayo ClinicOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04785820 | A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | completed | Phase 2 | 190 | Hoffmann-La RocheINDUSTRY | 18 | Mar 27, 2026 | clinicaltrials |
| NCT05145647 | To Observe the Benefit of Adding Brachytherapy After CCRT on Resectable Esophageal Cancer Patients Without Surgery | active not recruiting | N/A | 18 | Chang Gung Memorial HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06476678 | Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions | recruiting | — | 50 | Baylor College of MedicineOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07490340 | Trans-Oral Sampling as an Alternative Surveillance of Barrett's Esophagus Pilot(TOSS pilot) | active not recruiting | — | 60 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03044613 | Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06792786 | A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring | recruiting | N/A | 30 | The Central Hospital of Lishui CityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04312633 | Clinical Utility of WATS3D: A 5-Year Prospective Study | recruiting | — | 90,000 | CDx DiagnosticsINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06343597 | Volume Outcome Relationships and Effects | recruiting | — | 30 | Methodist Health SystemOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07481058 | KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer | recruiting | Phase 2 | 60 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07482566 | Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer(SIEWERT-RCT) | recruiting | N/A | 120 | Nurettin ŞahinOTHER_GOV | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT07482774 | Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma(TME-ESCC) | not yet recruiting | — | 12 | Nanjing Medical UniversityOTHER | 0 | Mar 19, 2026 | clinicaltrials |
| NCT02359968 | PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer(PROTECT) | completed | Phase 2 | 106 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02642809 | Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers | completed | Phase 1 | 16 | Washington University School of MedicineOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03301454 | Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer(E-DIS2) | terminated | Phase 2 | 15 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06735638 | Outside the Cage (OTC) Robotic Esophagectomy | not yet recruiting | Phase 1 | 31 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06335966 | BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy(BEST-RPP) | active not recruiting | — | 110 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07469241 | Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.(FUTURE-3) | not yet recruiting | Phase 2 | 50 | Fudan UniversityOTHER | 0 | Mar 13, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07464470 | Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers(GENCONCOR-2) | recruiting | — | 30 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT00587314 | The Effect of Ablation Therapy on Barrett's Esophagus(ablation IN BE) | enrolling by invitation | — | 600 | Mayo ClinicOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07104214 | Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy | recruiting | — | 5,000 | Zhejiang UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07175155 | Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients | recruiting | N/A | 410 | Zhejiang UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07457528 | Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC | recruiting | Phase 2 | 46 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07354295 | Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer （Radiogenomics-Esophagus） | recruiting | — | 1,500 | Shu PengOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03322267 | Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence | completed | Phase 2 | 26 | National Taiwan University HospitalOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07455019 | A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer | recruiting | Phase 2 | 28 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT00899626 | Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients | recruiting | — | 5,000 | Vanderbilt University Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04075305 | The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study(MOMENTUM) | recruiting | — | 8,000 | UMC UtrechtOTHER | 9 | Mar 5, 2026 | clinicaltrials |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 330 | I-Mab Biopharma US LimitedINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT04757363 | A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer | active not recruiting | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07448493 | Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer(GASTROBRAIN) | active not recruiting | — | 230 | Blokhin's Russian Cancer Research CenterOTHER | 2 | Mar 4, 2026 | clinicaltrials |
| NCT07446335 | A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 578 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03403465 | Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers | active not recruiting | Phase 2 | 90 | Duke UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06356311 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)(TroFuse-015) | active not recruiting | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Feb 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 14, 2026source: clinicaltrials